AZD4360 Trial for Advanced Solid Tumours
Phase 1/2
117
about 2.6 years
18–130
3 sites in CA, RI, TX
What this study is about
This trial is testing AZD4360 in adults with advanced solid tumours, including biliary tract cancer, gastric cancer, gastroesophageal junction cancer, and pancreatic ductal adenocarcinoma. It aims to assess the drug's safety, how well it works in the body (pharmacokinetics), its ability to cause an immune response, how effective it is against the tumour (preliminary efficacy), and overall tolerability.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take AZD4360
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of participants with Dose-Limiting Toxicity (in dose escalation cohort), Adverse events (AEs) , Serious Adverse Events (SAEs) and AEs leading to discontinuation of AZD4360
Secondary: Disease Control Rate (DCR), Duration of Response (DoR), Objective Response Rate (ORR), Overall Survival (OS), Plamsa PK parameters of AZD4360, total antibody and other analytes: Area Under Curve (AUC), Plasma PK parameters of AZD4360, total antibody and other analytes: Clearance, Plasma PK parameters of AZD4360, total antibody and other analytes: Half-life, Plasma PK parameters of AZD4360, total antibody and other analytes: Maximum plasma concentration (Cmax)